Tarsus Pharmaceuticals, Inc.
NASDAQ:TARSBiotechnology
+$0.29 today
- Market cap
- $3.74B
- Beta
- 0.51
- P/E (TTM)
- -55.9
- EPS (TTM)
- -$1.12
Volume 0.45M
Average 0.61M
TARS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Tarsus Pharmaceuticals, Inc.NASDAQ: TARS
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development growth accelerates
Q3 FY2026 research & development of $44.19M rose 171.4% year over year, ahead of the +83.0% change in trailing-twelve-month research & development. Sequentially, it rose 42.5% from the prior quarter. Over 3 fiscal years it compounded at +14.7% a year.
Context
- Research & development amounted to 14.3% of revenue in FY2025, down 14.9 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +171.4% holds above the trailing-twelve-month pace of +83.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 64.32M USD
- Year-over-year change
- +20.5%
- 4-year CAGR
- +11.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 64.32M | +20.5% |
| FY2024 | 2024-12-31 | 53.39M | +6.1% |
| FY2023 | 2023-12-31 | 50.31M | +18.0% |
| FY2022 | 2022-12-31 | 42.62M | +2.2% |
| FY2021 | 2021-12-31 | 41.71M | — |
Research & Development vs competitors
How TARS compares with its peers on the latest reported figures
- TARS's LTM Sep 2026 research & development of $115.59M is the highest of the 6 companies compared; the peer median is $15.36M.
- Its year-over-year change of +83.0% is the highest of 5, against a peer median of +15.4%.
- Research & development amounts to 16.9% of revenue for TARS, versus a peer median of 23.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $115.59M | +83.0% | +14.7% | 16.9% | |
| LTM Jun 2026 | $91.04M | +28.3% | -25.0% | 19.6% | |
| LTM Mar 2026 | $16.75M | -21.4% | +21.6% | 90.7% | |
| LTM Mar 2026 | $15.36M | +17.2% | +61.5% | 5.7% | |
| LTM Mar 2026 | $10.43M | +13.7% | -10.1% | 28.1% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $365.75K | — | — | — |
| Peer median (excluding TARS) | $15.36M | +15.4% | +5.7% | 23.8% | |
Competitors are the stored peer set for TARS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 57.03M | 25.82M | 17.45M | 182.95M | 451.36M |
| Cost of Revenue | 2.08M | 955K | 1.59M | 12.83M | 30.68M |
| Gross Profit | 54.95M | 24.86M | 15.85M | 170.13M | 420.68M |
| Gross Margin | 96.4% | 96.3% | 90.9% | 93.0% | 93.2% |
| Research & Development | 41.71M | 42.62M | 50.31M | 53.39M | 64.32M |
| Selling, General & Admin | 25.4M | 44.95M | 108.7M | 237.31M | 427.32M |
| Operating Expenses | 67.11M | 87.57M | 159.01M | 290.7M | 491.65M |
| Depreciation & Amortization | 312K | 326K | 877K | 1.23M | 1.82M |
| EBITDA | (13.46M) | (59.71M) | (131.67M) | (106.48M) | (53.61M) |
| EBITDA Margin | -23.6% | -231.3% | -754.7% | -58.2% | -11.9% |
| Operating Income | (12.16M) | (62.71M) | (143.16M) | (120.57M) | (70.97M) |
| Operating Margin | -21.3% | -242.9% | -820.5% | -65.9% | -15.7% |
| Interest Income | 36K | 3.5M | 10.34M | 15.01M | 15.75M |
| Interest Expense | 0 | 2.06M | 3.23M | 7.45M | 8.94M |
| Other Income / Expenses | (1.62M) | 617K | 7.27M | 5.02M | 6.61M |
| Income Before Tax | (13.77M) | (62.1M) | (135.89M) | (115.55M) | (64.36M) |
| Pre-Tax Margin | -24.1% | -240.5% | -778.9% | -63.2% | -14.3% |
| Income Tax Expense | 55K | (4K) | 0 | 0 | 2.06M |
| Net Income | (13.83M) | (62.09M) | (135.89M) | (115.55M) | (66.42M) |
| Net Margin | -24.2% | -240.5% | -778.9% | -63.2% | -14.7% |
| EPS (Basic) | (0.67) | (2.52) | (4.62) | (3.07) | (1.59) |
| EPS (Diluted) | (0.67) | (2.52) | (4.62) | (3.07) | (1.59) |
| Weighted Avg Shares | 20.55M | 24.62M | 29.38M | 37.6M | 41.78M |
| Weighted Avg Shares (Diluted) | 20.55M | 24.62M | 29.38M | 37.6M | 41.78M |
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
Intrinsic Alpha fair value
Locked
Current Price
$75.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.